Skip to main content
Top
Published in: World Journal of Surgery 7/2020

01-07-2020 | Original Scientific Report

Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules

Authors: L. Ravella, J. Lopez, F. Descotes, J. Giai, V. Lapras, M.-L. Denier, F. Borson-Chazot, J.-C. Lifante, M. Decaussin-Petrucci

Published in: World Journal of Surgery | Issue 7/2020

Login to get access

Abstract

Background

RAS and K601E BRAF mutations are not a reliable indicator of malignancy in fine-needle aspirations (FNA) of thyroid indeterminate cytologic nodules. We aimed to evaluate the histologic characteristics, the risk of malignancy associated with such mutations in FNA and their potential interest for preoperative clinical management of nodules.

Methods

We evaluated 69 indeterminate thyroid nodules with RAS or K601E BRAF mutations with available histopathologic follow-up. All FNA specimens were indeterminate according to the thyroid Bethesda system. Diagnosis of malignant, benign or indolent neoplasms was classified according to 2017 WHO classification. Carcinoma, NIFTP (noninvasive follicular thyroid neoplasm with papillary-like features) and WDTUMP (well-differentiated tumor of uncertain malignant potential) were considered “surgical,” as they require surgical excision. Adenoma was considered “non-surgical.” The risk of malignancy and the risk of “surgical disease” were evaluated.

Results

Pathologic evaluation of the 69 mutated nodules demonstrated benign, indolent and malignant histology in 17 cases (25%), 21 cases (30%) and 31 cases (45%), respectively. The risk of malignancy was 45%, and the risk of surgical disease was 75%. The majority of carcinomas were a follicular variant of papillary thyroid carcinoma. On follow-up, there have been no recurrences to date.

Conclusion

Preoperative RAS or BRAF K601E mutations detection in cytologic indeterminate thyroid nodules carries a high risk of surgical disease and may benefit from surgical management. Most surgical lesions harboring those mutations are low-risk tumors, which may be in favor of an initial lobectomy.
Literature
1.
go back to reference WHO (2017) WHO Classification of Tumours of Endocrine Organs. IARC WHO Classification of Tumours. vol. 10. Lloyd RV WHO (2017) WHO Classification of Tumours of Endocrine Organs. IARC WHO Classification of Tumours. vol. 10. Lloyd RV
2.
go back to reference McLeod DSA, Sawka AM, Cooper DS (2013) Controversies in primary treatment of low-risk papillary thyroid cancer. The Lancet. 381:1046–1057 McLeod DSA, Sawka AM, Cooper DS (2013) Controversies in primary treatment of low-risk papillary thyroid cancer. The Lancet. 381:1046–1057
3.
go back to reference Agretti P, Niccolai F, Rago T, De Marco G, Molinaro A, Scutari M et al (2014) BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. J Endocrinol Invest 37(10):1009–1014PubMed Agretti P, Niccolai F, Rago T, De Marco G, Molinaro A, Scutari M et al (2014) BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. J Endocrinol Invest 37(10):1009–1014PubMed
4.
go back to reference Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18):2164–2167PubMed Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18):2164–2167PubMed
5.
go back to reference Wémeau JL, Sadoul JL, d’Herbomez M, Monpeyssen H, Tramalloni J, Leteurtre E et al (2011) Recommandations de la Société française d’endocrinologie pour la prise en charge des nodules thyroïdiens. Presse Médicale 40(9):793–826 Wémeau JL, Sadoul JL, d’Herbomez M, Monpeyssen H, Tramalloni J, Leteurtre E et al (2011) Recommandations de la Société française d’endocrinologie pour la prise en charge des nodules thyroïdiens. Presse Médicale 40(9):793–826
6.
go back to reference Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW (2012) The bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol 56(4):333–339PubMed Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW (2012) The bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol 56(4):333–339PubMed
7.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133PubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133PubMedPubMedCentral
8.
go back to reference Alexander EK (2008) Approach to the patient with a cytologically indeterminate thyroid nodule. J Clin Endocrinol Metab 93(11):4175–4182PubMed Alexander EK (2008) Approach to the patient with a cytologically indeterminate thyroid nodule. J Clin Endocrinol Metab 93(11):4175–4182PubMed
9.
go back to reference Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMed Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMed
10.
go back to reference Ohori NP, Schoedel KE (2011) Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol 55(6):492–498PubMed Ohori NP, Schoedel KE (2011) Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol 55(6):492–498PubMed
11.
go back to reference Cibas ES, Ali SZ (2017) The 2017 bethesda system for reporting thyroid cytopathology: definitions, criteria, and explanatory notes, 2nd edn. Springer, New York Cibas ES, Ali SZ (2017) The 2017 bethesda system for reporting thyroid cytopathology: definitions, criteria, and explanatory notes, 2nd edn. Springer, New York
12.
go back to reference Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J et al (2012) Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367(8):705–715PubMed Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J et al (2012) Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367(8):705–715PubMed
13.
go back to reference Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL et al (2014) Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay: ThyroSeq NGS Test for Thyroid FNAs. Cancer 120(23):3627–3634PubMed Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL et al (2014) Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay: ThyroSeq NGS Test for Thyroid FNAs. Cancer 120(23):3627–3634PubMed
14.
go back to reference Nikiforov YE, Baloch ZW. Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology: Validation of ThyroSeq v3. Cancer Cytopathol [Internet]. 27 févr 2019 [cité 8 mars 2019]; Disponible sur: http://doi.wiley.com/10.1002/cncy.22112 Nikiforov YE, Baloch ZW. Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology: Validation of ThyroSeq v3. Cancer Cytopathol [Internet]. 27 févr 2019 [cité 8 mars 2019]; Disponible sur: http://​doi.​wiley.​com/​10.​1002/​cncy.​22112
15.
go back to reference Lasolle H, Riche B, Decaussin-Petrucci M, Dantony E, Lapras V, Cornu C et al (2017) Predicting thyroid nodule malignancy at several prevalence values with a combined Bethesda-molecular test. Transl Res 188(58–66):e1 Lasolle H, Riche B, Decaussin-Petrucci M, Dantony E, Lapras V, Cornu C et al (2017) Predicting thyroid nodule malignancy at several prevalence values with a combined Bethesda-molecular test. Transl Res 188(58–66):e1
16.
go back to reference Decaussin-Petrucci M, Descotes F, Depaepe L, Lapras V, Denier M-L, Borson-Chazot F et al (2017) Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Cytopathology 28(6):482–487PubMed Decaussin-Petrucci M, Descotes F, Depaepe L, Lapras V, Denier M-L, Borson-Chazot F et al (2017) Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Cytopathology 28(6):482–487PubMed
17.
go back to reference Torregrossa L, Viola D, Sensi E, Giordano M, Piaggi P, Romei C et al (2016) Papillary thyroid carcinoma with rare Exon 15 BRAF mutation has indolent behavior: a single-institution experience. J Clin Endocrinol Metab 101(11):4413–4420PubMed Torregrossa L, Viola D, Sensi E, Giordano M, Piaggi P, Romei C et al (2016) Papillary thyroid carcinoma with rare Exon 15 BRAF mutation has indolent behavior: a single-institution experience. J Clin Endocrinol Metab 101(11):4413–4420PubMed
18.
go back to reference Afkhami M, Karunamurthy A, Chiosea S, Nikiforova MN, Seethala R, Nikiforov YE et al (2016) Histopathologic and clinical characterization of thyroid tumors carrying the BRAFK601E mutation. Thyroid 26(2):242–247PubMed Afkhami M, Karunamurthy A, Chiosea S, Nikiforova MN, Seethala R, Nikiforov YE et al (2016) Histopathologic and clinical characterization of thyroid tumors carrying the BRAFK601E mutation. Thyroid 26(2):242–247PubMed
19.
go back to reference Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL et al (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690PubMedCentral Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL et al (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690PubMedCentral
20.
go back to reference Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR et al (2016) Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2(8):1023PubMedPubMedCentral Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR et al (2016) Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2(8):1023PubMedPubMedCentral
21.
go back to reference Suarez H, Du Villard J, Caillou B, Schlumberger M, Tubiana M, Parmentier C et al (1988) Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2(4):403–406PubMed Suarez H, Du Villard J, Caillou B, Schlumberger M, Tubiana M, Parmentier C et al (1988) Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2(4):403–406PubMed
22.
go back to reference Ibrahim AA, Wu HH (2016) Fine-needle aspiration cytology of noninvasive follicular variant of papillary thyroid carcinoma is cytomorphologically distinct from the invasive counterpart. Am J Clin Pathol 146(3):373–377PubMed Ibrahim AA, Wu HH (2016) Fine-needle aspiration cytology of noninvasive follicular variant of papillary thyroid carcinoma is cytomorphologically distinct from the invasive counterpart. Am J Clin Pathol 146(3):373–377PubMed
23.
go back to reference Amendoeira I, Maia T, Sobrinho-Simões M (2018) Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules. Endocr Relat Cancer 25(4):R247–R258PubMed Amendoeira I, Maia T, Sobrinho-Simões M (2018) Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules. Endocr Relat Cancer 25(4):R247–R258PubMed
24.
go back to reference Nikiforov YE (2011) Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 135(5):569–577PubMed Nikiforov YE (2011) Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 135(5):569–577PubMed
26.
go back to reference Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM et al (2017) American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid 27(4):481–483PubMed Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM et al (2017) American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid 27(4):481–483PubMed
27.
go back to reference Baloch ZW, Harrell RM, Brett EM, Randolph G, Garber JR, On behalf of AACE Endocrine Surgery Scientific Committee and Thyroid Scientific Committee (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Disease state commentary: managing thyroid tumors diagnosed as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Pract 23(9):1153–1158 Baloch ZW, Harrell RM, Brett EM, Randolph G, Garber JR, On behalf of AACE Endocrine Surgery Scientific Committee and Thyroid Scientific Committee (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Disease state commentary: managing thyroid tumors diagnosed as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Pract 23(9):1153–1158
28.
go back to reference Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF et al (2015) The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid 25(9):987–992PubMed Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF et al (2015) The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid 25(9):987–992PubMed
29.
go back to reference Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M et al (2016) Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in the bethesda system for reporting thyroid cytopathology: reclassifying NI-FVPTC. Cancer Cytopathol 124(3):181–187PubMed Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M et al (2016) Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in the bethesda system for reporting thyroid cytopathology: reclassifying NI-FVPTC. Cancer Cytopathol 124(3):181–187PubMed
30.
go back to reference Hung YP, Barletta JA (2018) A user’s guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Histopathology 72(1):53–69PubMed Hung YP, Barletta JA (2018) A user’s guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Histopathology 72(1):53–69PubMed
31.
go back to reference Johnson DN, Sadow PM (2018) Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol 82:32–38PubMed Johnson DN, Sadow PM (2018) Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol 82:32–38PubMed
32.
go back to reference Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88(6):2745–2752PubMed Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88(6):2745–2752PubMed
33.
go back to reference Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR et al (2011) BRAFK601E mutation in a patient with a follicular thyroid carcinoma. Thyroid 21(12):1393–1396PubMed Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR et al (2011) BRAFK601E mutation in a patient with a follicular thyroid carcinoma. Thyroid 21(12):1393–1396PubMed
34.
go back to reference Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G et al (2004) BRAF mutations are not a major event in post-chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89(9):4267–4271PubMed Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G et al (2004) BRAF mutations are not a major event in post-chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89(9):4267–4271PubMed
35.
go back to reference Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P et al (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 446(6):589–595PubMed Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P et al (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 446(6):589–595PubMed
36.
go back to reference Patel SG, Carty SE, McCoy KL, Ohori NP, LeBeau SO, Seethala RR et al (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery 161(1):168–175PubMed Patel SG, Carty SE, McCoy KL, Ohori NP, LeBeau SO, Seethala RR et al (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery 161(1):168–175PubMed
37.
go back to reference Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J (1985) Papillary carcinoma of the thyroid a clinicopathologic study of 247 cases treated at the university of florence, Italy. Cancer 55:805–828PubMed Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J (1985) Papillary carcinoma of the thyroid a clinicopathologic study of 247 cases treated at the university of florence, Italy. Cancer 55:805–828PubMed
38.
go back to reference Faquin WC, Baloch ZW (2010) Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 38:731–739PubMed Faquin WC, Baloch ZW (2010) Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 38:731–739PubMed
39.
go back to reference Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M et al (2013) RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab 98(5):E914–E922PubMedPubMedCentral Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M et al (2013) RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab 98(5):E914–E922PubMedPubMedCentral
40.
go back to reference Lemoine N, Mayall E, Wyllie F, Williams E, Goyns M, Stringer B et al (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4(2):159–164PubMed Lemoine N, Mayall E, Wyllie F, Williams E, Goyns M, Stringer B et al (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4(2):159–164PubMed
41.
go back to reference Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T, Machinami R (2000) Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 196:1–7PubMed Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T, Machinami R (2000) Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 196:1–7PubMed
42.
go back to reference Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E et al (2000) N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone métastases and inverse correlation to thyroglobulin expression. Thyroid 10(1):19–23PubMed Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E et al (2000) N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone métastases and inverse correlation to thyroglobulin expression. Thyroid 10(1):19–23PubMed
43.
go back to reference Nikiforov YE, Yip L, Nikiforova MN (2013) New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin Cancer Res 19(9):2283–2288PubMed Nikiforov YE, Yip L, Nikiforova MN (2013) New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin Cancer Res 19(9):2283–2288PubMed
44.
go back to reference Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL et al (2011) Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96(11):3390–3397PubMedPubMedCentral Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL et al (2011) Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96(11):3390–3397PubMedPubMedCentral
45.
go back to reference Burns JS, Blaydes JP, Wright PA, Lemoine L, Bond JA (1992) Stepwise transformation of primary thyroid epitheliai cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression. Mol Carcinog 6:129–139PubMed Burns JS, Blaydes JP, Wright PA, Lemoine L, Bond JA (1992) Stepwise transformation of primary thyroid epitheliai cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression. Mol Carcinog 6:129–139PubMed
46.
go back to reference Weiss A, Parina RP, Tang JA, Brumund KT, Chang DC, Bouvet M (2015) Outcomes of thyroidectomy from a large California state database. Am J Surg 210(6):1170–1177PubMed Weiss A, Parina RP, Tang JA, Brumund KT, Chang DC, Bouvet M (2015) Outcomes of thyroidectomy from a large California state database. Am J Surg 210(6):1170–1177PubMed
47.
go back to reference Colonna M, Uhry Z, Guizard AV, Delafosse P, Schvartz C, Belot A et al (2015) Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol 39(4):511–518PubMed Colonna M, Uhry Z, Guizard AV, Delafosse P, Schvartz C, Belot A et al (2015) Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol 39(4):511–518PubMed
48.
go back to reference Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP (2016) Systematic review of trends in the incidence rates of thyroid cancer. Thyroid 26(11):1541–1552PubMed Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP (2016) Systematic review of trends in the incidence rates of thyroid cancer. Thyroid 26(11):1541–1552PubMed
Metadata
Title
Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules
Authors
L. Ravella
J. Lopez
F. Descotes
J. Giai
V. Lapras
M.-L. Denier
F. Borson-Chazot
J.-C. Lifante
M. Decaussin-Petrucci
Publication date
01-07-2020
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 7/2020
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-020-05487-1

Other articles of this Issue 7/2020

World Journal of Surgery 7/2020 Go to the issue